Bone quality in patients with acromegaly

Česká verzia

Authors: Martin Kužma ¹; Ivana Ságová ²; Dušan Pávai ³; Peter Jackuliak ¹; Zdenko Killinger ¹; Peter Vaňuga ³; Juraj Payer ¹
Authors place of work: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava, Slovenská republika ¹; I. interná klinika JLF UK a UNM, Slovenská republika ²; Národný endokrinologický a diabetologický ústav, Ľubochňa, Slovenská republika ³
Published in the journal: Vnitř Lék 2017; 63(9): 589-592
Category: Reviews

Summary

The impact of acromegaly on bone and the risk of fractures has not been sufficiently investigated. GH hypersecretion stimulates bone turnover, leading to an increase in bone turnover markers. Normal or even increased bone mineral density (BMD) in comparison to healthy controls have been reported, but there are some works where decreased BMD was observed among acromegaly patients with hypogonadism, particularly at lumbar spine. Less pronounced effect of GH overproduction was observed at the femoral neck, as explained by the positive effect of hypersecretion on the cortical bone (due to periosseal ossification). Several studies have documented morphometric vertebral fractures (VF) in 1/3 of acromegaly patients. The major risk factors leading to the development of VF include hypogonadism, diabetes mellitus and previous VF. Because the risk of fractures does not correlate with BMD most of the studies are currently focused on bone quality, bone strength and microstructure.

Key words:
bone microstructure – growth hormone – IGF1 – vertebral fractures

Zdroje

1. Pivonello R, Auriemma RS, Grasso LFS et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 2017; 20(1): 46–62. Dostupné z DOI: <http://dx.doi.org/10.1007/s11102–017–0797–7>.

2. Mazziotti G, Biagioli E, Maffezzoni F et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2015; 100(2): 384–394. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014–2937>.

3. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008; 29(5): 535–559. Dostupné z DOI: <http://dx.doi.org/10.1210/er.2007–0036>.

4. Mazziotti G, Chiavistelli S, Giustina A. Pituitary diseases and bone. Endocrinol Metab Clin North Am 2015; 44(1):171–180. <http://dx.doi.org/10.1016/j.ecl.2014.10.014>.

5. Halse J, Melsen F, Mosekilde L. Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinol 1981; 97(1): 18–22.

6. Kayath MJ, Vieira JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int 1997; 7(3): 226–230.

7. Riggs BL, Randall RV, Wahner HW et al. The nature of the metabolic bone disorder in acromegaly. J Clin Endocrinol Metab 1972; 34(6): 911–918.

8. Vestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly--a potential beneficial effect of growth hormone. Osteoporos Int 2004; 15(2): 155–159.

9. Madeira M, Neto LV, de Paula Paranhos Neto F et al. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 2013; 98(4): 1734–1741. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012–4073>.

10. Maffezzoni F, Maddalo M, Frara S et al. High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. Endocrine 2016; 54(2): 532–542.

11. Killinger Z, Kuzma M, Sterancakova L et al. Osteoarticular changes in acromegaly. Int J Endocrinol 2012; 2012: 839282. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/839282>.

12. Scillitani A, Chiodini I, Carnevale V et al. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res 1997; 12(10):1729–1736.

13. Stepan J, Marek J, Havranek T et al. Bone isoenzyme of serum alkaline phosphatase in acromegaly. Clin Chim Acta 1979; 93(3): 355–363.

14. Ueland T, Bollerslev J, Godang K et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. Eur J Endocrinol 2001; 145: 685–690.

15. Kamenicky P, Mazziotti G, Lombes M et al. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev 2014; 35(2): 234–281. Dostupné z DOI: <http://dx.doi.org/10.1210/er.2013–1071>.

16. Halupczok-Zyla J, Jawiarczyk-Przybylowska A, Bolanowski M. Patients with Active Acromegaly are at High Risk of 25(OH)D Deficiency. Front Endocrinol (Lausanne) 2015; 6:89. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2015.00089>.

17. Diamond T, Nery L, Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 1989; 111(7): 567–573.

18. Claessen KM, Mazziotti G, Biermasz NR et al. Bone and Joint Disorders in Acromegaly. Neuroendocrinology 2016; 103(1): 86–95. Dostupné z DOI: <http://dx.doi.org/10.1159/000375450>.

19. Malgo F, Hamdy NAT, Papapoulos SE et al. Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site. Osteoporos Int 2017; 28(8): 2433–2437. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–017–4054–8>.

20. Harvey NC, Gluer CC, Binkley N et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 2015; 78: 216–224. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2015.05.016>.

21. Hong AR, Kim JH, Kim SW et al. Trabecular bone score as a skeletal fragility index in acromegaly patients. Osteoporos Int 2016; 27(3): 1123–1129. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3344–2>.

22. Godang K, Olarescu NC, Bollerslev J et al. Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study. Eur J Endocrinol 2016; 175(2): 155–164. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-16–0340>.

23. Bonadonna S, Mazziotti G, Nuzzo M et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005; 20(10): 1837–1844.

24. Genant HK, Jergas M, Palermo L et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996; 11(7):984–996.

25. Mazziotti G, Bianchi A, Porcelli T et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 2013; 98(8): 3402–3410. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–1460>.

26. Claessen KM, Kroon HM, Pereira AM et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab 2013; 98(12): 4808–4815. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–2695>.